338 related articles for article (PubMed ID: 34091704)
1. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
Rodriguez-Pla A; Vikram HR; Khalid V; Wesselius LJ
Rheumatol Int; 2021 Aug; 41(8):1509-1514. PubMed ID: 34091704
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis.
Schramm MA; Venhoff N; Wagner D; Thiel J; Huzly D; Craig-Mueller N; Panning M; Hengel H; Kern WV; Voll RE
Front Immunol; 2020; 11():2086. PubMed ID: 32983161
[TBL] [Abstract][Full Text] [Related]
3. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e731-e735. PubMed ID: 34217677
[TBL] [Abstract][Full Text] [Related]
4. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
Lancman G; Mascarenhas J; Bar-Natan M
J Hematol Oncol; 2020 Oct; 13(1):131. PubMed ID: 33008453
[TBL] [Abstract][Full Text] [Related]
5. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
7. COVID-19-induced granulomatosis with polyangiitis.
Selvaraj V; Moustafa A; Dapaah-Afriyie K; Birkenbach MP
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33737283
[TBL] [Abstract][Full Text] [Related]
8. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
9. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
[TBL] [Abstract][Full Text] [Related]
10. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
11. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
12. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.
Guilpain P; Le Bihan C; Foulongne V; Taourel P; Pansu N; Maria ATJ; Jung B; Larcher R; Klouche K; Le Moing V
Ann Rheum Dis; 2021 Jan; 80(1):e10. PubMed ID: 32312768
[No Abstract] [Full Text] [Related]
14. Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report.
Billi B; Cholley P; Grobost V; Clément M; Rieu V; Le Guenno G; Lobbes H
Front Immunol; 2024; 15():1399180. PubMed ID: 38707896
[TBL] [Abstract][Full Text] [Related]
15. Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.
Nakamura Y; Okumura F; Nihei M; Chubachi K; Sakamoto H; Ishioka Y; Makiguchi T; Tanaka H; Taima K; Yajima N; Kurose A; Tasaka S
Intern Med; 2023; 62(4):589-593. PubMed ID: 36792217
[TBL] [Abstract][Full Text] [Related]
16. Prostatitis, a rare presentation of granulomatosis with polyangiitis, successfully treated with rituximab and prednisone.
Shaukat MS; Ocon AJ; Peredo RA; Bhatt BD
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30108118
[TBL] [Abstract][Full Text] [Related]
17. Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications.
Spinicci M; Mazzoni A; Coppi M; Antonelli A; Salvati L; Maggi L; Basile G; Graziani L; Di Lauria N; Di Pilato V; Kiros ST; Beccastrini E; Saccardi R; Angileri M; Cecchi M; Cusi MG; Rossolini GM; Annunziato F; Bartoloni A; Parronchi P
J Clin Immunol; 2022 Oct; 42(7):1371-1378. PubMed ID: 35779200
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature.
Armağan B; Eksin MA; Güven SC; Özdemir B; Dağlı PA; Küçükşahin O; Omma A; Erden A
Turk J Med Sci; 2022 Aug; 52(4):899-909. PubMed ID: 36326380
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis.
Merkel PA; Niles JL; Mertz LE; Lehane PB; Pordeli P; Erblang F
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1372-1378. PubMed ID: 32475029
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
